AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12042586 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA-BDP (hydrofluoroalkane beclomethasone dipropionate) at half the daily dose (100 to 200 microg)
Number of subjects: 300
Study 12042586 — intervention group
Group type: COMPARATOR
Intervention: CFC-BDP (chlorofluorocarbon beclomethasone dipropionate) + spacer at approximately the same dose (200 to 400 microg)
Number of subjects: 300
Study 12042586 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA-BDP
Number of subjects: 300
Study 12042586 — intervention group
Group type: COMPARATOR
Intervention: CFC-BDP + S
Number of subjects: 300
Study 9461367 — intervention group
Group type: COMPARATOR
Intervention: High serum total cholesterol (TC) levels in females
Number of subjects: 548
Study 9461367 — intervention group
Group type: EXPERIMENTAL
Intervention: High total cholesterol levels
Number of subjects: 548
Study 7620754 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 60 mg/day
Number of subjects: 398
Study 7620754 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 398
Study 2198635 — intervention group
Group type: COMPARATOR
Intervention: Captopril 50 mg (single dose)
Number of subjects: 88
Study 2198635 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 50 mg (single dose) + Hydrochlorothiazide 50 mg
Number of subjects: 88
Study 2198635 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of Captopril 50 mg + Hydrochlorothiazide 50 mg
Number of subjects: 88
Study 2198635 — intervention group
Group type: EXPERIMENTAL
Intervention: Three doses of Captopril 50 mg + Hydrochlorothiazide 50 mg
Number of subjects: 88
Study 363253 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen CAFVP (Adriamycin, cyclophosphamide, 5-fluorouracil, vincristine, prednisone)
Number of subjects: 148
Study 363253 — intervention group
Group type: COMPARATOR
Intervention: Regimen CMFVP (cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisone)
Number of subjects: 148
Study 31803980 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate alcohol consumption
Number of subjects: 0
Study 31803980 — intervention group
Group type: EXPERIMENTAL
Intervention: Large, multiyear randomized controlled trial
Number of subjects: 0
Study 31803980 — intervention group
Group type: EXPERIMENTAL
Intervention: Health policy recommendations
Number of subjects: 0
Study 31155415 — intervention group
Group type: EXPERIMENTAL
Intervention: delNS1‐H5N1 vaccine at 6.8 log10 TCID50/subject
Number of subjects: 0
Study 31155415 — intervention group
Group type: EXPERIMENTAL
Intervention: delNS1‐H5N1 vaccine at 7.5 log10 TCID50/subject
Number of subjects: 0
Study 31155415 — intervention group
Group type: EXPERIMENTAL
Intervention: delNS1‐H5N1 vaccine after 2nd immunization
Number of subjects: 0
Study 31155415 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28169561 — intervention group
Group type: EXPERIMENTAL
Intervention: Bike desk intervention (4 class hours/week for 5 months)
Number of subjects: 44
Study 28169561 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal class hours)
Number of subjects: 44
Study 26151264 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 371
Study 26151264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 371
Study 23642856 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab therapy
Number of subjects: 65
Study 21315873 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive information
Number of subjects: 72
Study 21315873 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery
Number of subjects: 72
Study 21315873 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 72
Study 19765849 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IP)
Number of subjects: 61
Study 19765849 — intervention group
Group type: COMPARATOR
Intervention: Control (no ischemic preconditioning)
Number of subjects: 61
Study 17223996 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone + CRH stimulation (1 mg overnight and 2 mg over two days)
Number of subjects: 55
Study 17223996 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin stimulation
Number of subjects: 55
Study 17223996 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone + CRH stimulation
Number of subjects: 55
Study 15129744 — intervention group
Group type: EXPERIMENTAL
Intervention: Cued side of fixation
Number of subjects: 0
Study 15129744 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncued locations
Number of subjects: 0
Study 15129744 — intervention group
Group type: EXPERIMENTAL
Intervention: Directional bias in IOR effect
Number of subjects: 0
Study 11960536 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary PCI
Number of subjects: 451
Study 11960536 — intervention group
Group type: COMPARATOR
Intervention: Thrombolytic therapy
Number of subjects: 451
Study 9800534 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibrotactile speech perception aid
Number of subjects: 0
Study 9800534 — intervention group
Group type: COMPARATOR
Intervention: Hearing aids
Number of subjects: 0
Study 8562145 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomised consent design
Number of subjects: 0
Study 8562145 — intervention group
Group type: COMPARATOR
Intervention: Standard informed consent
Number of subjects: 0
Study 2227289 — intervention group
Group type: EXPERIMENTAL
Intervention: Diets containing the most carbohydrate (50%-80%) for 2 weeks
Number of subjects: 27
Study 2227289 — intervention group
Group type: EXPERIMENTAL
Intervention: Diets containing the most fat (40%) for 2 weeks
Number of subjects: 27
Study 2227289 — intervention group
Group type: EXPERIMENTAL
Intervention: Altering diets by increasing protein and decreasing carbohydrate content by 30% for 24 hours
Number of subjects: 27
Study 2227289 — intervention group
Group type: COMPARATOR
Intervention: Maintaining or altering diets for 24 hours
Number of subjects: 27
Study 116480 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 37
Study 116480 — intervention group
Group type: EXPERIMENTAL
Intervention: Glipizide
Number of subjects: 37
Study 116480 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 37
Study 31996235 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimune intervention (12-month access)
Number of subjects: 360
Study 31996235 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 360
Study 30557099 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipegfilgrastim
Number of subjects: 2489
Study 29888520 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviour Change Techniques (BCTs) delivered by physiotherapists during SOLAS classes
Number of subjects: 8
Study 26646074 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy (according to Touch Therapy) for four days from the first day postnatal
Number of subjects: 50
Study 26646074 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 50
Study 24931572 — intervention group
Group type: EXPERIMENTAL
Intervention: Bionic pancreas
Number of subjects: 52
Study 24931572 — intervention group
Group type: COMPARATOR
Intervention: Insulin pump
Number of subjects: 52
Study 23011184 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab 0.3 mg
Number of subjects: 0
Study 23011184 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab 0.5 mg
Number of subjects: 0
Study 19228234 — intervention group
Group type: EXPERIMENTAL
Intervention: Gold standard treatment (acetaminophen/paracetamol or non-steroidal anti-inflammatory drugs, and exercise and/or physical therapy)
Number of subjects: 212
Study 19228234 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional and non-traditional treatments
Number of subjects: 212
Study 19228234 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher education
Number of subjects: 212
Study 19228234 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-White race
Number of subjects: 212
Study 17708864 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk intervention
Number of subjects: 11
Study 17708864 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium intervention
Number of subjects: 11
Study 17708864 — intervention group
Group type: COMPARATOR
Intervention: Control group (calcium supplement)
Number of subjects: 11
Study 15371985 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim 160 mg orally twice daily for 4 days
Number of subjects: 10
Study 15371985 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin 600 mg orally once daily for 5 days
Number of subjects: 10
Study 15371985 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 11219473 — intervention group
Group type: EXPERIMENTAL
Intervention: Almotriptan 12.5 mg
Number of subjects: 1173
Study 11219473 — intervention group
Group type: COMPARATOR
Intervention: Sumatriptan 50 mg
Number of subjects: 1173
Study 9439556 — intervention group
Group type: EXPERIMENTAL
Intervention: Gliclazide (80 to 320 mg/d) for 2 years
Number of subjects: 5572
Study 8177670 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided laboratory approach (lab group)
Number of subjects: 46
Study 8177670 — intervention group
Group type: COMPARATOR
Intervention: Lecture and nonexperimental learner-centered activities (comparison group)
Number of subjects: 46
Study 2846022 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin (0.5 mg orally)
Number of subjects: 6
Study 2846022 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 6
Study 31157575 — intervention group
Group type: COMPARATOR
Intervention: Itraconazole pulse therapy (Group I)
Number of subjects: 30
Study 31157575 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined long-pulsed Nd:Yag laser and itraconazole pulse therapy (Group II)
Number of subjects: 30
Study 29701045 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous embedding of thumb-tack needle combined with mytear
Number of subjects: 80
Study 29701045 — intervention group
Group type: COMPARATOR
Intervention: 0.1% sodium hyaluronate eye drop (alice), four times per day for two weeks
Number of subjects: 80
Study 27062851 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous kyphoplasty (PKP) by unilateral approach (group A)
Number of subjects: 22
Study 27062851 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous kyphoplasty (PKP) by bilateral approach (group B)
Number of subjects: 22
Study 27062851 — intervention group
Group type: EXPERIMENTAL
Intervention: Both unilateral and bilateral approaches
Number of subjects: 22
Study 24739260 — intervention group
Group type: EXPERIMENTAL
Intervention: 3g/d LCn‐3s
Number of subjects: 153
Study 24739260 — intervention group
Group type: COMPARATOR
Intervention: 12-week nutrition and exercise education program plus olive oil (P‐LC)
Number of subjects: 153
Study 24739260 — intervention group
Group type: EXPERIMENTAL
Intervention: education program plus LCn‐3s (EX+N‐3)
Number of subjects: 153
Study 24739260 — intervention group
Group type: COMPARATOR
Intervention: education groups (OO+N‐3)
Number of subjects: 153
Study 24739260 — intervention group
Group type: COMPARATOR
Intervention: education program
Number of subjects: 153
Study 23732774 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic cystogastrostomy
Number of subjects: 40
Study 23732774 — intervention group
Group type: COMPARATOR
Intervention: Surgical cystogastrostomy
Number of subjects: 40
Study 21218643 — intervention group
Group type: EXPERIMENTAL
Intervention: Phloroglucinol 80 mg daily for 3 days
Number of subjects: 74
Study 21218643 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 74
Study 18581214 — intervention group
Group type: EXPERIMENTAL
Intervention: History of incarceration
Number of subjects: 581
Study 15390130 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine agonists (either in monotherapy or in combination)
Number of subjects: 202
Study 15390130 — intervention group
Group type: COMPARATOR
Intervention: Control PD patients (not specified how many)
Number of subjects: 202
Study 12820866 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (4 mg)
Number of subjects: 13
Study 12820866 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 10763520 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingent Feedback
Number of subjects: 48
Study 10763520 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncontingent Feedback
Number of subjects: 48
Study 10763520 — intervention group
Group type: EXPERIMENTAL
Intervention: Success Conditions
Number of subjects: 48
Study 10763520 — intervention group
Group type: EXPERIMENTAL
Intervention: Failure Conditions
Number of subjects: 48
Study 10763520 — intervention group
Group type: COMPARATOR
Intervention: Control Group (Reading Passage)
Number of subjects: 48
Study 8851613 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (500 mg twice a day for 3 days)
Number of subjects: 40
Study 8851613 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin (400 mg once daily for 3 days)
Number of subjects: 40
Study 8243814 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox (250 mg)
Number of subjects: 8
Study 8243814 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 3084015 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestrogen treatment
Number of subjects: 104
Study 3084015 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 104
Study 31718918 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional bimaxillary surgery (n=6)
Number of subjects: 13
Study 31718918 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular autorotation (n=7)
Number of subjects: 13
Study 29351885 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS + CPT
Number of subjects: 103
Study 29351885 — intervention group
Group type: COMPARATOR
Intervention: sham + CPT
Number of subjects: 103
Study 27105949 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-mm ultra-minimally invasive ultrasound-guided carpal tunnel release
Number of subjects: 92
Study 27105949 — intervention group
Group type: COMPARATOR
Intervention: 2-cm blind mini-open carpal tunnel release
Number of subjects: 92
Study 25728891 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic resection
Number of subjects: 119
Study 25728891 — intervention group
Group type: COMPARATOR
Intervention: Open resection
Number of subjects: 119
Study 22827479 — intervention group
Group type: EXPERIMENTAL
Intervention: SmartClip self‐ligating brackets
Number of subjects: 18
Study 22827479 — intervention group
Group type: COMPARATOR
Intervention: Conventional standard edgewise brackets
Number of subjects: 18
Study 21668767 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal blood sampling (FBS) performed according to predefined criteria
Number of subjects: 2827
Study 21668767 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal blood sampling (FBS) not performed according to predefined criteria
Number of subjects: 2827
Study 18512508 — intervention group
Group type: EXPERIMENTAL
Intervention: Beveled direct resin composite restorations (Adper Single Bond/Filtek Z250) after 24 h
Number of subjects: 80
Study 18512508 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonbeveled direct resin composite restorations (Adper Single Bond/Filtek Z250) after 24 h
Number of subjects: 80
Study 18512508 — intervention group
Group type: EXPERIMENTAL
Intervention: Beveled direct resin composite restorations (Adper Single Bond/Filtek Z250) after 180 days
Number of subjects: 80
Study 18512508 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonbeveled direct resin composite restorations (Adper Single Bond/Filtek Z250) after 180 days
Number of subjects: 80
Study 18512508 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect composite restorations (prepolymerized Filtek Z250 cemented with Adper Single Bond/Rely X ARC) after 180 days
Number of subjects: 80
Study 18512508 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal cycling and water storage
Number of subjects: 80
Study 18512508 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonbeveled restorations
Number of subjects: 80
Study 18512508 — intervention group
Group type: EXPERIMENTAL
Intervention: Beveled restorations
Number of subjects: 80
Study 18512508 — intervention group
Group type: COMPARATOR
Intervention: Sound teeth (control group)
Number of subjects: 80
Study 17157121 — intervention group
Group type: EXPERIMENTAL
Intervention: FEX60/PSE120
Number of subjects: 784
Study 17157121 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 784
Study 14617226 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramlintide (120 μg bid) + insulin
Number of subjects: 166
Study 14617226 — intervention group
Group type: COMPARATOR
Intervention: Placebo + insulin
Number of subjects: 166
Study 10766095 — intervention group
Group type: EXPERIMENTAL
Intervention: Woman-specific data
Number of subjects: 0
Study 10766095 — intervention group
Group type: COMPARATOR
Intervention: Breast-specific data
Number of subjects: 0
Study 9042663 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (IFN) therapy
Number of subjects: 0
Study 9042663 — intervention group
Group type: COMPARATOR
Intervention: Busulfan (BU) monotherapy
Number of subjects: 0
Study 1565551 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin prophylaxis
Number of subjects: 264
Study 1565551 — intervention group
Group type: EXPERIMENTAL
Intervention: Tympanostomy tube insertion
Number of subjects: 264
Study 1565551 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264
Study 3907825 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin at a dose of 60 mg/m2 every 3 weeks, total dose of 550 mg/m2
Number of subjects: 32
Study 3907825 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide at a dose of 1500 mg/m2 every 3 weeks for 1 year
Number of subjects: 32
Study 31212376 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival entrepreneurship strategies
Number of subjects: 45
Study 31212376 — intervention group
Group type: EXPERIMENTAL
Intervention: Entrepreneurial processes
Number of subjects: 45
Study 28287920 — intervention group
Group type: EXPERIMENTAL
Intervention: Future alone social exclusion condition
Number of subjects: 253
Study 28287920 — intervention group
Group type: COMPARATOR
Intervention: Future belonging condition
Number of subjects: 253
Study 28287920 — intervention group
Group type: COMPARATOR
Intervention: No feedback condition
Number of subjects: 253
Study 27219721 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-layer-coating implant
Number of subjects: 120
Study 27219721 — intervention group
Group type: COMPARATOR
Intervention: Standard TKA implant
Number of subjects: 120
Study 24423146 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice plus cognitive behavioural intervention (CBI)
Number of subjects: 701
Study 24423146 — intervention group
Group type: COMPARATOR
Intervention: Advice
Number of subjects: 701
Study 22230474 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 g mushroom powder
Number of subjects: 10
Study 22230474 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 g mushroom powder
Number of subjects: 10
Study 22230474 — intervention group
Group type: COMPARATOR
Intervention: 0 g mushroom powder (control)
Number of subjects: 10
Study 20124517 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole (400 mg daily)
Number of subjects: 131
Study 20124517 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin (600 mg daily)
Number of subjects: 131
Study 17671288 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive modafinil (mean dose, 177 mg/day)
Number of subjects: 85
Study 17671288 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 17671288 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive modafinil
Number of subjects: 85
Study 16081235 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centered communication style
Number of subjects: 159
Study 16081235 — intervention group
Group type: COMPARATOR
Intervention: Disease-centered communication style
Number of subjects: 159
Study 16081235 — intervention group
Group type: COMPARATOR
Intervention: Emotion-centered communication style
Number of subjects: 159
Study 11815983 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver-coated polyurethane catheters (BactiGuard; Metacot, Stockholm, Sweden), n = 120
Number of subjects: 233
Study 11815983 — intervention group
Group type: COMPARATOR
Intervention: Uncoated standard polyurethane catheters (Cavatheter, Fresenius AG, Bad Homburg, Germany), n = 113
Number of subjects: 233
Study 9972860 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethaphan (peripheral nicotinic receptor antagonist)
Number of subjects: 12
Study 9972860 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 12
Study 9972860 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual brand of cigarette
Number of subjects: 12
Study 9972860 — intervention group
Group type: EXPERIMENTAL
Intervention: Denicotinized tobacco cigarettes
Number of subjects: 12
Study 9972860 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine-injected cigarettes
Number of subjects: 12
Study 7726398 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol administered at 1 mg/kg lean body mass followed by a 4-hour infusion at 5 mg.kg-1.h-1 during hypothermia (34 degrees C)
Number of subjects: 6
Study 7726398 — intervention group
Group type: COMPARATOR
Intervention: Propofol administered at 1 mg/kg lean body mass followed by a 4-hour infusion at 5 mg.kg-1.h-1 during normothermia (37 degrees C)
Number of subjects: 6
Study 7726398 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 0.5 mg/kg administered as an intravenous bolus during hypothermia (34 degrees C)
Number of subjects: 6
Study 7726398 — intervention group
Group type: COMPARATOR
Intervention: Atracurium 0.5 mg/kg administered as an intravenous bolus during normothermia (37 degrees C)
Number of subjects: 6
Study 1319523 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (1 mg) administered before injection of LA
Number of subjects: 20
Study 1319523 — intervention group
Group type: COMPARATOR
Intervention: Control group without sedation
Number of subjects: 20
Study 6719042 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (Bayer) 500 mg
Number of subjects: 0
Study 6719042 — intervention group
Group type: EXPERIMENTAL
Intervention: Reumyl (Hässle) 500 mg
Number of subjects: 0
Study 6719042 — intervention group
Group type: EXPERIMENTAL
Intervention: Premaspin (Lääke) 500 mg
Number of subjects: 0
Study 30837595 — intervention group
Group type: EXPERIMENTAL
Intervention: ENGAGE (structured play-based intervention)
Number of subjects: 60